Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.01015-2015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of two interferon-gamma release assays for pediatric tuberculosis infection.
J Pediatric Infect Dis Soc
January 2025
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, USA.
Introduction: Identifying tuberculosis infection (TBI) using interferon-gamma release assays (IGRAs) is a primary component of clinical and public health efforts to prevent pediatric tuberculosis. Pediatric data comparing the two IGRAs in the United States are very limited. We compared the performance of the two IGRAs among a large pediatric cohort tested for TBI and assessed whether discordance might be due to quantitative results close to test cut-off values.
View Article and Find Full Text PDFThe Utility of Interferon-γ Release Assays in the Diagnosis of Tuberculosis in Patients With Cancer.
Transpl Infect Dis
December 2024
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Patients with cancer are at elevated risk for tuberculosis (TB) reactivation. Diagnosis of latent TB infection and TB disease remains challenging in this patient population despite the advent of interferon-γ release assays (IGRA).
Methods: We retrospectively reviewed medical records of all patients with cancer who had IGRA testing (QuantiFERON-TB [QFT-TB] or T-SPOT.
Low concordance between QIAreach QuantiFERON-TB, a novel interferon-gamma release assay, and QuantiFERON-TB Gold Plus, in a population-based survey in Blantyre, Malawi.
J Clin Microbiol
December 2024
Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Unlabelled: Urgent improvements in the diagnosis and management of infection are required to reach End TB goals. Conventional interferon-gamma release assays (IGRAs), such as QuantiFERON-TB Gold Plus (QFT-Plus), require substantial laboratory infrastructure and large blood volumes, limiting use in high-burden settings. The QIAreach QuantiFERON-TB (QIAreach QFT) was developed to overcome these challenges but has not previously been evaluated in field conditions in a low-income, high-burden country, or at scale in children.
View Article and Find Full Text PDFPerformance of the T-SPOT.TB test in patients with indeterminate QuantiFERON-TB Gold Plus results: proposal for an algorithm for the diagnosis of Latent Tuberculosis Infection.
Infez Med
December 2024
Clinical Microbiology and Virology Laboratory, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Latent Tuberculosis Infection (LTBI) is a state of persistent immune response to complex antigens without clinical, radiological and microbiological signs of active disease. Effective diagnosis and preventive treatment of LTBI are crucial for tuberculosis (TB) control, especially in high-risk groups. Currently, two main tests are used for LTBI diagnosis: the Tuberculin Skin Test (TST) and the Interferon-Gamma Release Assays (IGRA), including the QuantiFERON-TB Gold Plus (QFT-Plus) and the T-SPOT.
View Article and Find Full Text PDFCost-effectiveness of diagnostic technologies for mycobacterium tuberculosis infection in India and Brazil.
PLOS Glob Public Health
November 2024
Department of Infectious Disease and Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Article Synopsis
- The study evaluates the cost and effectiveness of new skin-based tests and blood-based assays for tuberculosis in high-burden countries like India and Brazil.
- Results show that Diaskintest is more cost-effective than the traditional PPD-tuberculin test (TST) for diagnosing TB, with costs of $22.6 in Brazil and $41.0 in India per correctly diagnosed case.
- While Diaskintest is cheaper, TSPOT.TB blood test is more effective despite its higher cost, with an incremental cost-effectiveness ratio of $74 in India and $55 in Brazil.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!